spacer
home > pmps > winter 2015 > common knowledge
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Common Knowledge

Currently, estimates suggest that it costs well over $1 billion to take a drug from discovery to market, in a process taking, on average, 12 years, but potentially lasting as many as 16, or even 20. If the patent for a drug is filed in year one, normally it will expire 20 years later, allowing for just eight years of exploitation by its owner, or – in a worst case scenario – no time at all. Once the patent has expired, it becomes available to rival companies who are able to exploit the drug without having made any investment in its discovery or development. Thus, the product becomes a copycat drug or, more accurately, a generic drug.

Generic: The Unbranding of Modern Medicine reviews the evolution of the generic drug industry from a group of mid-20th century copycats into a surprisingly powerful set of multinational corporations still in existence in the 21st century. Somewhat regrettably for us in Europe, the book focuses its account on the social, political and cultural history of generic drugs in the US.

Over the past 20 years, generic drugs have become objects of great interest. They have expanded from taking less than 10% of overall market share to providing more than 80% of all the prescriptions filled in the US today. This is an evolution that neither stakeholders in healthcare, nor producers of drugs that are in patent, can afford to ignore. It is fair to say that without generic drugs in their present form, healthcare across the world would be considerably more expensive and, in many cases, unaffordable by national governments.

This deeply researched and annotated book traces the history of generic drugs from initial scandals surrounding the alleged bribery of an FDA official and the suppression of data by The Boots Company, to the present-day situation where generic drugs are regulated just as tightly by the FDA and EMA as their pre-generic counterparts. There is also coverage of the naming and branding of generic drugs and the argument over what constitutes a generic, as well as the science of similarity and significance of differences between generic drugs and their precursors.

In addition, the book examines the current regulatory situation – concentrating largely on the US – and talks about the paradoxes of generic consumption in the clinic, pharmacy and, eventually, the supermarket. The author also discusses the science and politics of the so-called ‘me-too’ drugs, and briefly evaluates the international generic scene. In the final conclusion, he reviews what he refers to as the crisis of similarity, starting with a debate on the controversial topic of biosimilarity – an issue presenting a novel challenge to regulators. Biosimilars are prime examples of what Professor Greene calls “the same but not the same” drugs, and he worries about whether the introduction of generic drugs paid for by the state heralds a future where the loss of individual choice, market incentives, innovation and creativity will all be replaced by the embrace of the state.

It is rare for scientific treatises to be as readable and enjoyable as Generic: The Unbranding of Modern Medicine. I recommend the book to anyone interested in the past and future of generic pharmaceuticals.

Generic: The Unbranding of Modern Medicine by Jeremy A Greene is published by Johns Hopkins University Press. ISBN: 1-4214-1493-7

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

FlyPharma Europe

22-23 October 2019, Copenhagen, Denmark

The FlyPharma Conference Europe 2019 is aimed at forward-thinking individuals and businesses that are ready to uncover the potential in their pharma supply chain. The event offers an interactive platform to discuss current and future challenges within pharma and cargo, with topics including market trends, cold chain innovations, latest regulatory demands, security technology, and how to encourage collaboration between supply chain players. There will be plenty of networking opportunities, including a complimentary evening networking event, where delegates can meet and catch up with senior and executive pharma and cargo professionals – gaining strong, new industry contacts and building on existing ones.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement